Jeuveau Claims To Be The Most Affordable Wrinkle Injectable — But Is It Legit?
“Black Don’t Crack” Kept Me From Getting Fillers So, what’s the difference between Jeuveau and Botox? Like Botox, Dysport, and Xeomin, Jeuveau is used to temporarily improve the appearance of frown lines between the eyebrows — technically called the glabellar lines, but often referred to as the “11s.” (Off-label, wrinkle relaxers are also used to treat other areas, like crow’s feet around the eyes and smile lines.) Like Botox, Jeuveau has a molecular weight of 900 kDa, but they’re produced in different facilities and are derived from different strains of the same toxin. (Botox, or onabotulinumtoxinA, is made by Allergan in Westport, Ireland; Jeuveau, or prabotulinumtoxinA, comes out of Seoul, South Korea.) The risks and potential side effects listed by the companies are also identical. The main draw for consumers is that Jeuveau’s parent company, Evolus, has announced plans to price the product at a premium; analysts estimate a 20-30% price reduction overall. Whereas Botox has medical indications (treating migraines, etc.), and was in fact first used in the medical market before it was approved for cosmetics, Jeuveau is purely cosmetic and not subject to any insurance coverage or reimbursement. Skirting medical-industry vetting saves the company and providers money, and patients by extension. The company is also offering customer incentives, including a $75 consumer coupon (called “#NEWTOXNOW”) launching July 1 and a full loyalty program on the way. Advertisement Then there’s the marketing strategy, which is perhaps most essential of all to understanding why Jeuveau is rocking the neurotoxin world, and how Evolus predicts it will gain a competitive advantage. “The most novel thing about Jeuveau is its unique marketing strategy — targeting younger millennials in a fresher way, with emojis, an app, diverse models, and lots of pink,” says Lara Devgan , MD, a New York City plastic surgeon and RealSelf chief medical officer who attended the industry event in Cancun. In fact, Dr. Devgan says, the main reason that patients are curious about Jeuveau in the first place is because they’ve seen its marketing efforts. “I don’t think Jeuveau is converting current Botox patients, necessarily,” she says. “Rather, I suspect that it is appealing to a whole new group of consumers that is aging into the aesthetic marketplace today.” Is one wrinkle relaxer “better” than the other? In a word, no. “Each wrinkle relaxer on the market has a similar effect but slightly different personality — not necessarily better, but just different from others,” says celebrity cosmetic dermatologist and PFRANKMD & Skin Salon founder Paul Jarrod Frank, MD, who has not yet used Jeuveau nor is affiliated with the brand. “I use all of them regularly, often at the same time on the same patient. Jeuveau certainly won’t replace the other neuromodulators.” If there’s one thing about Jeuveau that’s “better” than the mainstays it’ll be competing with, it’s the affordability. “While cost is important, we do not want to sacrifice quality,” says dermatologist and Director of Cosmetic and Clinical Research in Dermatology at Mount Sinai Hospital Joshua Zeichner, MD, who is not currently affiliated with Allergan but has worked as a consultant and speaker for the brand in the past. “Different manufacturing processes can affect the quality of a product, its effectiveness, and its safety. One thing that history tells us is that even though ingredient lists are identical, two products may perform very differently in the real world.” Advertisement For what it’s worth, the Allergan factory that produces Botox is notoriously meticulous, a 61-acre fortress with 25 years of neurotoxin-making history behind it. The company isn’t exactly forthcoming about the process, which hasn’t changed since it was first approved by the FDA as a medical product to treat eye-muscle disorders in 1989; in fact, it’s top secret. Evolus is similarly tight-lipped, though claims in its press release that Jeuveau is produced in a modern “state-of-the-art facility” using a trademarked purification method known as Hi-Pure. Jeuveau received FDA approval five years after Evolus submitted a license application for its particular preparation. As for anecdotal evidence from subjects that the results of Jeuveau may last longer than those of its competitors based on the company’s initial data, Dr. Devgan, who’s already using it in her practice, isn’t buying it. “I think that is an inaccurate statement that represents liberties being taken with the data interpretation,” she says. “There has been no research that demonstrates a statistically significant difference in duration as compared to other neurotoxins.” Where can you get Jeuveau? Jeuveau is currently rolling out nationwide in the offices of board-certified dermatologists, plastic surgeons, and other licensed medical professionals; as always, exact prices will vary between doctors. Some providers are already using it, so it’s worth asking your doctor if you’re interested — even if their invite to the Ritz got lost in the mail. Advertisement
Hollow Brook Wealth Management LLC Purchases Shares of 21,951 PFSweb, Inc. (NASDAQ:PFSW)
Hollow Brook Wealth Management LLC Purchases Shares of 21,951 PFSweb, Inc. (NASDAQ:PFSW) Hollow Brook Wealth Management LLC Purchases Shares of 21,951 PFSweb, Inc. (NASDAQ:PFSW) – Filed Under – by Tyrone Williams Filed Under: Finance – SEC Filing Articles Tweet Hollow Brook Wealth Management LLC purchased a new position in shares of PFSweb, Inc. (NASDAQ:PFSW) during the 1st quarter, Holdings Channel reports. The fund purchased 21,951 shares of the business services provider’s stock, valued at approximately $114,000.
Other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of PFSweb in the 4th quarter worth about $58,000. Rhumbline Advisers increased its position in shares of PFSweb by 52.7% in the 4th quarter. Rhumbline Advisers now owns 19,506 shares of the business services provider’s stock worth $100,000 after purchasing an additional 6,728 shares during the last quarter. Bank of America Corp DE increased its position in shares of PFSweb by 41.7% in the 4th quarter. Bank of America Corp DE now owns 20,569 shares of the business services provider’s stock worth $105,000 after purchasing an additional 6,052 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of PFSweb by 7.8% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 37,100 shares of the business services provider’s stock worth $193,000 after purchasing an additional 2,700 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of PFSweb by 6.9% in the 1st quarter. Wells Fargo & Company MN now owns 38,650 shares of the business services provider’s stock worth $201,000 after purchasing an additional 2,511 shares during the last quarter. 57.65% of the stock is currently owned by hedge funds and other institutional investors.
Get PFSweb alerts: Shares of NASDAQ PFSW traded up $0.10 during midday trading on Monday, hitting $3.75. The company’s stock had a trading volume of 14,344 shares, compared to its average volume of 67,436. PFSweb, Inc. has a 1-year low of $3.50 and a 1-year high of $11.01. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.09 and a current ratio of 1.14. The firm has a market capitalization of $71.43 million, a PE ratio of 12.93 and a beta of 0.62.
PFSweb (NASDAQ:PFSW) last posted its quarterly earnings results on Thursday, May 9th. The business services provider reported ($0.02) EPS for the quarter. PFSweb had a net margin of 0.25% and a return on equity of 12.07%. The business had revenue of $72.15 million during the quarter.
Several research firms have recently weighed in on PFSW. Craig Hallum downgraded shares of PFSweb from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Lake Street Capital set a $10.00 target price on shares of PFSweb and gave the stock a “buy” rating in a research report on Tuesday, March 19th. They noted that the move was a valuation call. Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price (down previously from $12.00) on shares of PFSweb in a research report on Tuesday, March 19th. TheStreet lowered shares of PFSweb from a “c-” rating to a “d” rating in a report on Friday, May 10th. Finally, ValuEngine lowered shares of PFSweb from a “hold” rating to a “sell” rating in a report on Monday, June 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $9.44.
In other news, Director Benjamin L. Rosenzweig bought 6,868 shares of PFSweb stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $5.04 per share, with a total value of $34,614.72. Following the purchase, the director now directly owns 6,868 shares of the company’s stock, valued at approximately $34,614.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Also, Director Benjamin L. Rosenzweig bought 9,868 shares of PFSweb stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $5.02 per share, with a total value of $49,537.36. Following the completion of the purchase, the director now directly owns 6,868 shares in the company, valued at $34,477.36. The disclosure for this purchase can be found here . Insiders bought a total of 18,971 shares of company stock valued at $93,292 over the last ninety days. Company insiders own 6.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2019/06/10/hollow-brook-wealth-management-llc-purchases-shares-of-21951-pfsweb-inc-nasdaqpfsw.html.
PFSweb, Inc provides omni-channel commerce solutions in the United States, Europe, Canada, and India. It operates through two segments, LiveArea Professional Services and PFS Operations. The company offers strategic commerce consulting services, including commerce strategy, omni-channel consulting, digital opportunity audit, organizational/operational readiness, and platform evaluation/selection services; and design and digital marketing services, such as design, user experience, interactive development, search engine optimization and paid search, affiliate marketing, conversion optimization, storefront management, email marketing, and digital analytics.
Read More: Dividend Yield
Want to see what other hedge funds are holding PFSW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PFSweb, Inc. (NASDAQ:PFSW).